Table 3 Patient demographic and baseline characteristics-FAS
Variables | Biomarker positive N = 18 | Biomarker negative N = 11 |
|---|---|---|
Age in years, median (range) | 55.0(36.0–77.0) | 54.0(39.0–69.0) |
Sex | ||
Female | 18(100.0) | 10(90.9) |
Male | 0(0.0) | 1(9.1) |
Countries | ||
China | 16(88.9) | 11(100.0) |
US | 2(11.1) | 0(0.0) |
Races | ||
Asian | 16(88.89) | 11(100.00) |
Black | 1(5.56) | 0(0.0) |
White | 1(5.56) | 0(0.0) |
Postmenopausal or menopausal status | ||
Pre-menopausal | 5(27.8) | 3(27.3) |
Perimenopausal | 4(22.2) | 0(0.0) |
Postmenopausal | 9(50.0) | 7(63.6) |
Not Reported | 0(0.0) | 1(9.1) |
ECOG performance-status score | ||
0 | 0(0.0) | 0(0.0) |
1 | 18(100.00) | 11(100.00) |
PgR-positive | ||
Yes | 15(83.3) | 7(63.6) |
No | 3(16.7) | 4(36.4) |
Sites of metastases | ||
Lymph nodes | 12(66.7) | 7(63.6) |
Bone | 13(72.2) | 5(45.5) |
Lungs | 13(72.2) | 5(45.5) |
Liver | 9(50.0) | 4(36.4) |
Brain | 1(5.6) | 0(0) |
Breast | 2(11.1) | 2(18.2) |
Other | 6(33.3) | 3(27.3) |
Visceral metastasis | ||
Yes | 15(83.3) | 9(81.8) |
No | 3(16.7) | 2(18.2) |
Previous systemic therapy | ||
One line | 15(83.3) | 6(54.5) |
Two lines | 3(16.7) | 5(45.5) |
Number of prior endocrine therapy lines | ||
None | 1(5.6) | 1(9.1) |
One line | 14(77.8) | 10(90.9) |
Two lines | 3(16.7) | 0(0.0) |
Chemotherapy | ||
Neoadjuvant or adjuvant chemotherapy | 8(44.4) | 5(45.5) |
For advanced breast cancer | 3(16.7) | 6(54.6) |
Prior CDK4/6 therapies | ||
Yes | 13(72.2) | 5(45.5) |
No | 5(22.2) | 6(54.5) |
Not Reported | 0 | 0 |
